



# Market Announcement

9 February 2023

---

## Exopharm Limited (ASX: EX1) – Trading Halt

### Description

The securities of Exopharm Limited ('EX1') will be placed in trading halt at the request of EX1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 13 February 2023 or when the announcement is released to the market.

### Issued by

**Nicholas Mountain**

Adviser, Listings Compliance

For personal use only

9 February 2023

ASX Limited  
Listings Compliance, Perth  
Level 40 Central Park  
152-158 St Georges Terrace  
PERTH, WA, 6000

Attention: Mr Sean Maloney (Adviser, Listings Compliance (Perth))

By Email Only: tradinghaltsperth@asx.com.au

Dear Mr Maloney,

### TRADING HALT REQUEST

Exopharm Limited [ASX:EX1] (**Company or Exopharm**) hereby requests a trading halt in relation to the Company's ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding an update on the Company's ongoing financial position and financing arrangements (**the Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist Exopharm in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.
- Exopharm requests that the trading halt remain in place until the earlier of commencement of normal trading on Monday, 13 February 2023, or when the announcement regarding the stated Purpose is released to the market.
- Exopharm is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

For and on behalf of the Board of Exopharm Limited.

Yours faithfully,

**Mr Jason Watson**  
Chairman

*By the Board – this release has been authorised by the Board.*

### Company and Media Enquiries:

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Ian Dixon

Managing Director

Tel: +61 418 561 907

[ian.dixon@exopharm.com](mailto:ian.dixon@exopharm.com)

### ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.

Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines - **LEAP** manufacturing technology, **LOAD** API loading technologies and **EVPS** tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

In addition, Exopharm is using its technology platform to enable its own product development programs - each aimed at delivering a transformative medicine for an unmet medical need.

## FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.

For personal use only